iOrganBio emerged from stealth with $2 million in seed funding and introduced CellForge, an AI‑driven cell manufacturing platform aimed at producing predictable, reproducible human cells and organoids. The Chapel Hill startup said CellForge combines high‑throughput automation with AI models and a Functional Human Cell Atlas to tune differentiation and scale production for drug discovery and regenerative therapies. Founders include former Guardant Health and academic stem‑cell leaders; early investors include IndieBio and First Star Ventures. iOrganBio said the platform enables real‑time adjustments to culture conditions to meet defined biological profiles and supports cGMP translation. If the platform delivers reproducible, high‑quality human cells at scale, it could shorten timelines for disease modeling and cell therapy manufacturing; investors and partners will watch validation and customer adoption closely.